Health Robotics Issues Price Increase in Compliance With The Patient Protection and Affordable Care Act (ACA)
BOZEN, Sud-Tirol, Italy, December 27, 2012 /PRNewswire/ --
Health Robotics today announced that, effective January 1, 2013, it will fully comply with The Patient Protection and Affordable Care Act (ACA), including maximum health insurance benefits for its USA-based employees. Health Robotics is hopeful that its USA-based customers understand the need for small companies such as Health Robotics to transfer these additional operating costs and ACA's mandatory excise [sales] taxes on FDA-regulated medical devices equally to both its USA not-for-profit [tax-exempt customers] and for-profit customers, effective March 1, 2013.
Gaspar DeViedma, Health Robotics' Executive Vice President and Board Member, stated: "Although USA-based operating companies may opt out of certain ACA mandates such as health insurance coverage by hiring part-time employees or by other well documented methods, Health Robotics recently made a decision after the November 6, 2012 elections to fully comply with the ACA given the life-critical nature of our business. In order to offer our prospective customers a reasonable time to obtain approval of their pending budgets, the price increase shall be effective for all contracts/orders received on or after March 1, 2013, with all current quotes expiring thereafter, or subject to price modifications that reflect the ACA."
About Health Robotics:
Founded in 2006 and now reaching well over 80% global market share, Health Robotics is the undisputed leading supplier of life-critical intravenous medication robots, providing over 300 hospital installations in 5 continents with robotics-based technology and fully integrated clinical software automation solutions. Health Robotics' second generation solutions [i.v.STATION, i.v.SOFT, and i.v.STATION ONCO] have been found [through scientific and peer-reviewed studies,] to greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' medical devices and integrated workflow solutions help hospitals eliminate life-threatening drug and diluent exchange errors, improve drug potency, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
1. Impact of Robotic Antineoplastic Preparation on Safety, Workflow, Costs. Seger, Churchill, Keohane, Belisle, Wong, Sylvester, Chesnick, Burdick, Wien, Cotugno, Bates, and Rothschild. Brigham & Women's Hospital, Massachusetts College of Pharmacy, and Harvard Medical School. Journal of Oncology Practice, Nov. 2012, Volume 8, number 6.
2. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin®, Remicade®, and Herceptin®. Peters, Capelle, Arvinte, van de Garde. St. Antonius Hospital. mAbs January 2013, Volume 5, Issue 1.
For additional information, please contact:
SOURCE Health Robotics